Biomarkers for Risk Stratification After STEMI
Launched by MEDICAL UNIVERSITY OF WARSAW · Nov 7, 2018
Trial Information
Current as of May 12, 2025
Unknown status
Keywords
ClinConnect Summary
Heart failure is nowadays one of the leading problems in cardiology. Heart failure is associated with high morbidity and mortality, as well as high social costs, resulting mainly from a large number of hospitalizations. Galectin-3 and ST-2 have an important role in remodeling and fibrosis of the left ventricle, one of the key pathophysiological mechanisms leading to the development of heart failure. Galectin-3 is a protein secreted by activated macrophages, that stimulate inflammation and fibrosis of the myocardium. ST2 molecule is a soluble glycoprotein belonging to the family of interleuk...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \>= 18 years
- • signed consent
- • first STEMI treated with PCI
- Exclusion Criteria:
- • previous STEMI/non-STEMI,
- • pre-existing HF,
- • severe renal dysfunction (plasma creatinine level \>220 mmol/L and/or creatinine clearance \<30 mL/min),
- • severe liver disease,
- • chronic inflammatory disease,
- • current neoplastic disease,
- • life expectancy \<1 year.
About Medical University Of Warsaw
The Medical University of Warsaw is a leading academic institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to excellence in medical training and clinical practice, the university actively engages in a diverse range of clinical trials aimed at improving patient outcomes and enhancing medical knowledge. With a robust infrastructure and a multidisciplinary team of experts, the Medical University of Warsaw fosters collaboration in the development of novel therapies and interventions, contributing significantly to the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, , Poland
Patients applied
Trial Officials
Agnieszka Kapłon-Cieślicka, PhD
Study Chair
1st Chair and Department of Cardiology, Medical University of Warsaw
Grzegorz Opolski, Professor
Study Chair
1st Chair and Department of Cardiology, Medical University of Warsaw
Krzysztof J Filipiak, Professor
Study Chair
1st Chair and Department of Cardiology, Medical University of Warsaw
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials